Keywords: Biosililars, Adoption, Nephrologiests, Epoetin alfa, Biosililar insulins, Decision Resources, USA, Europe, Japan

US nephrologists expect rapid adoption of USA's first biosimilars - epoetin alfa

Article | 09 October 2012

More than 60% of surveyed nephrologists in the USA expect to begin prescribing biosimilar epoetin alfa within the first 12 months of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in